Texture analysis on MR images helps predicting non-response to NAC in breast cancer

BMC Cancer

Volumn 15, Issue 1, 2015, Pages

  Michoux, N ^a   Van den Broeck, S ^a   Lacoste, L ^a   Fellah, L ^a   Galant, C ^a   Berliere M ^a   Leconte, I ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

Breast cancer; MRI; Neoadjuvant chemotherapy; Texture analysis

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; TAXANE DERIVATIVE; TRASTUZUMAB; ANTINEOPLASTIC AGENT; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; BREAST IMAGING REPORTING AND DATA SYSTEM PARAMETERS; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER MORPHOLOGY; CLASSIFIER; HISTOLOGY; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; KINETIC PARAMETERS; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PREDICTION; RADIOLOGICAL PARAMETERS; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; IMAGE PROCESSING; METABOLISM; MIDDLE AGED; NEOADJUVANT THERAPY; PATHOLOGY; PROGNOSIS; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM GRADING; PROGNOSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84938579445     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-015-1563-8     Document Type: Article

References (62)

1. Kaufmann M, von Minckwitz G, Smith R, Valero V, Gianni L, Eiermann W, et al. International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. J Clin Oncol. 2003;21:2600-8.
2. Heys SD, Hutcheon AW, Sarkar TK, Ogston KN, Miller ID, Payne S, et al. Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial. Clin Breast Cancer. 2002;3:S69-74.
3. Van der Hage JA, van de Velde CJ, Julien JP, Tubiana-Hulin M, VanderveldenC DL. Preoperative chemotherapyin primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol. 2001;19:4224-32.
4. Mieog JS, van der Hage JA, van de Velde CJ. Preoperative chemotherapy for women with operable breast cancer. Cochrane Database Syst Rev. 2007;18:CD005002.
5. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998;16:2672-85.
6. Barbi GP, Marroni P, Bruzzi P, Nicolò G, Paganuzzi M, Ferrara GB. Correlation between steroid hormone receptors and prognostic factors in human breast cancer. Oncology. 1987;44:265-9.
7. von Minckwitz G, Sinn HP, Raab G. Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast. Breast Cancer Res. 2008;10:R30.
8. Esserman LJ, Kaplan E, Partridge S, Tripathy D, Rugo H, Park J, et al. MRI phenotype is associated with response to doxorubicin and cyclophosphamide neoadjuvant chemotherapy in Stage III breast cancer. Ann Surg Oncol. 2001;8:549-59.
9. Nishimura R, Osako T, Okumura Y, Hayashi M, Arima N. Clinical significanceof Ki-67 in neoadjuvant chemotherapy for primary breast cancer as a predictor for chemosensitivity and for prognosis. Breast Cancer. 2010;17:269-75.
10. Fangberget A, Nilsen LB, Hole KH, Holmen MM, Engebraaten O, Naume B, et al. Neoadjuvant chemotherapy in breast cancer-response evaluation and prediction of response to treatment using dynamic contrast-enhanced and diffusion-weighted MR imaging. Eur Radiol. 2011;21:1188-99.
11. Press MF, Sauter G, Buyse M, Bernstein L, Guzman R, Santiago A, et al. Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy. J Clin Oncol. 2011;29:859-67.
12. Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, Elledge R, et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet. 2003;362:362-9.
13. von Minckwitz G, Untch M, Blohmer JU, Costa SD, Eidtmann H, Fasching PA, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012;30:1796-804.
14. Woodhams R, Matsunaga K, Iwabuchi K, Kan S, Hata H, Kuranami M, et al. Diffusion-weighted imaging of malignant breast tumors: the usefulness of apparent diffusion coefficient (ADC) value and ADC map for the detection of malignant breast tumors and evaluation of cancer extension. J Comput Assist Tomogr. 2005;29:644-9.
15. Woodhams R, Kakita S, Hata H, Iwabuchi K, Kuranami M, Gautam S, et al. Identification of residual breast carcinoma following neoadjuvant chemotherapy: diffusion-weighted imaging--comparison with contrast-enhanced MR imaging and pathologic findings. Radiology. 2010;254:357-66.
16. Wu L-M, Hu J-N, Gu H-Y, Hua J, Chen J, Xu J-R. Can diffusion-weighted MR imaging and contrast-enhanced MR imaging precisely evaluate and predict pathological response to neoadjuvant chemotherapy in patients with breast cancer? Breast Cancer Res Treat. 2012;135:17-28.
17. Tozaki M, Sakamoto M, Oyama Y, Maruyama K, Fukuma E. Predicting pathological response to neoadjuvant chemotherapy in breast cancer with quantitative 1H MR spectroscopy using the external standard method. J Magn Reson Imaging. 2010;31:895-902.
18. Murata Y, Hamada N, Kubota K, Miyatake K, Tadokoro M, Kataoka Y, et al. Choline by magnetic spectroscopy and dynamic contrast enhancement curve by magnetic resonance imaging in neoadjuvant chemotherapy for invasive breast cancer. Mol Med Rep. 2009;2:39-43.
19. Ah-See ML, Makris A, Taylor NJ, Harrison M, Richman PI, Burcombe RJ, et al. Early changes in functional dynamic magnetic resonance imaging predict for pathologic response to neoadjuvant chemotherapy in primary breast cancer. Clin Cancer Res. 2008;14:6580-9.
20. Martincich L, Montemurro F, De Rosa G, Marra V, Ponzone R, Cirillo S, et al. Monitoring response to primary chemotherapy in breast cancer using dynamic contrast-enhanced magnetic resonance imaging. Breast Cancer Res Treat. 2004;83:67-76.
21. Li SP, Makris A, Beresford MJ, Taylor NJ, Ah-See ML, Stirling JJ, et al. Use of dynamic contrast enhanced MR imaging to predict survival in patients with primary breast cancer undergoing neoadjuvant chemotherapy. Radiology. 2011;260:68-78.
22. Loo CE, Teertstra HJ, Rodenhuis S, van de Vijver MJ, Hannemann J, Muller SH, et al. Dynamic contrast-enhanced MRI for prediction of breast cancer response to neoadjuvant chemotherapy: initial results. AJR Am J Roentgenol. 2008;191:1331-8.
23. de Bazelaire C, Calmon R, Thomassin I, Brunon C, Hamy AS, Fournier L, et al. Accuracy of perfusion MRI with high spatial but low temporal resolution to assess invasive breast cancer response to neoadjuvant chemotherapy: a retrospective study. BMC Cancer. 2011;11:361.
24. Uematsu T, Kasami M, Yuen S. Neoadjuvant chemotherapy for breast cancer: correlation between the baseline MR imaging findings and responses to therapy. Eur Radiol. 2010;20:2315-22.
25. Pickles MD, Manton DJ, Lowry M, Turnbull LW. Prognostic value of pre-treatment DCE-MRI parameters in predicting disease free and overall survival for breast cancer patients undergoing neoadjuvant chemotherapy. Eur J Radiol. 2009;71:498-505.
26. Craciunescu OI, Blackwell KL, Jones EL, Macfall JR, Yu D, Vujaskovic Z, et al. DCE-MRI parameters have potential to predict response of locally advanced breast cancer patients to neoadjuvant chemotherapy and hyperthermia: a pilot study. Int J Hyperthermia. 2009;25:405-15.
27. Bhooshan N, Giger ML, Jansen SA, Li H, Lan L, Newstead GM. Cancerous breast lesions on dynamic contrast-enhanced MR images: computerized characterization for image-based prognostic markers. Radiology. 2010;254:680-90.
28. Holli K, Lääperi AL, Harrison L, Luukkaala T, Toivonen T, Ryymin P, et al. Characterization of breast cancer types by texture analysis of magnetic resonance images. Acad Radiol. 2010;17:135-41.
29. Haralick RM, Dinstein I, Shanmugan K. Textural features for image classification. IEEE Trans Syst Man Cybern. 1973;SMC-3:610-21.
30. Zhang Y, Moore GR, Laule C, Bjarnason TA, Kozlowski P, Traboulsee A, et al. Pathological correlates of magnetic resonance imaging texture heterogeneity in multiple sclerosis. Ann Neurol. 2013;74:91-9.
31. Hajek M, Dezortova M, Materka A, Lerski R. Texture analysis for magnetic resonance imaging. Czech Republic: Med4 publishing; 2006. ISBN: 978-80-903660-0-8.
32. Gibbs P, Turnbull LW. Textural analysis of contrast-enhanced MR images of the breast. Magn Reson Med. 2003;50:92-8.
33. Ahmed A, Gibbs P, Pickles M, Turnbull L. Texture analysis in assessment and prediction of chemotherapy response in breast cancer. J Magn Reson Imaging. 2013;38:89-101.
34. Nie K, Chen J-H, Yu HJ, Chu Y, Mehta RS, Nalcioglu O, Su M-Y. Quantitative analysis of MRI tumor characteristics for neoadjuvant chemotherapy response prediction in breast cancer to the first-line doxorubicin-cyclophosphamide regimen and the AC followed by Taxane Regimen. In Proceedings of the 15th International Society for Magnetic Resonance in Medicine, abstract 558. Berlin: Publisher International Society for Magnetic Resonance in Medicine (ISMRM); 2007.
35. Sahoo S, Lester SC. Pathology of breast carcinomas after neoadjuvant chemotherapy: an overview with recommendations on specimen processing and reporting. Arch Pathol Lab Med. 2009;133:633-42.
36. Mudduwa L. Pathological parameters predicting HER-2/neu status of breast carcinoma. J Diagn Pathol. 2006;5:13-8.
37. American College of Radiology. Breast imaging reporting and data system (BI-RADS). 4th ed. Reston: American College of Radiology; 2003.
38. Liney G, Gibbs P, Hayes C, Leach MO, Turnbull LW. Dynamic contrast-enhanced MRI in the differentiation of breast tumours: user defined versus semi-automated region-of-interest analysis. J Magn Reson Imaging. 1999;10:945-9.
39. Likas A, Vlassis N, Verbeek JJ. The global k-means clustering algorithm. Pattern Recogn. 2003;36:451-61.
40. Tang X. Texture information in run-length matrices. IEEE Trans Image Process. 1998;7:1602-9.
41. Armitage P, Berry G, Matthews JNS. Statistical methods in medical research. 4th ed. Oxford: Blackwell Science; 2002.
42. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a non parametric approach. Biometrics. 1988;44:837-45.
43. Pampel FC. Logistic regression: A primer. Thousand Oaks, California: Sage University Papers Series on Quantitative Applications in the Social Sciences; 2000. p. 7-132.
44. Baumann K. Cross-validation as the objective function for variable-selection techniques. Trends Anal Chem. 2003;22:395-406.
45. Rothman KJ. No adjustments are needed for multiple comparisons. Epidemiology. 1990;1:43-6.
46. Place AE, Jin Huh S, Polyak K. The microenvironment in breast cancer progression: biology and implications for treatment. Breast Cancer Res. 2011;13:227-38.
47. Kuhl C. The current status of breast MR imaging. Part I. Choice of technique, image interpretation, diagnostic accuracy, and transfer to clinical practice. Radiology. 2007;244:356-78.
48. Kershaw LE, Cheng H-L M. Temporal resolution and SNR requirements for accurate DCE-MRI data analysis using the AATH model. Magn Reson Med. 2010;64:1772-80.
49. Yang C, Karczmar GS, Medved M, Oto A, Zamora M, Stadler WM. Reproducibility assessment of a multiple reference tissue method for quantitative dynamic contrast enhanced-MRI analysis. Magn Reson Med. 2009;61:851-9.
50. Li X, Welch EB, Chakravarthy AB, Xu L, Arlinghaus LR, Farley J, et al. Statistical comparison of dynamic contrast-enhanced MRI pharmacokinetic models in human breast cancer. Magn Reson Med. 2012;68:261-71.
51. Castellano G, Bonilha L, Li LM, Cendes F. Texture analysis of medical images. Clin Radiol. 2004;59:1061-9.
52. Ojala T, Pietikäinen M, Mäenpää T. Multiresolution gray-scale and rotation invariant texture classification with local binary patterns. IEEE Trans Pattern Anal Mach Intell. 2002;24:971-87.
53. Joshi MS, Bartakke PP, Sutaone MS. Texture representation using autoregressive models Advances in Computational Tools for Engineering Applications. In Proceedings Advances in Computational Tools for Engineering Applications, International Conference ACTEA: Beirut. 2009. 380-385: doi: 10.1109/ACTEA.2009.5227958 .
54. Depeursinge A, Foncubierta-Rodríguez A, Van De Ville D, Müller H. Multiscale lung texture signature learning using the Riesz transform. In: Proceedings of the 15th Medical Image Computing and Computer-Assisted Intervention (MICCAI), vol. 7512. Nice: Lecture Notes in Computer Science; 2012. p. 517-24.
55. Loizou CP, Murray V, Pattichis MS, Seimenis I, Pantziaris M, Pattichis CS. Multiscale amplitude-Modulation frequency-modulation (AM-FM) texture analysis of multiple sclerosis in brain MRI images. IEEE Trans Info Tech Biomed. 2011;15:119-28.
56. Drabycz S, Mitchell JR. Texture quantification of medical images using a novel complex space-frequency transform. Int J CARS. 2008;3:465-75.
57. Mallat SG. A theory for multiresolution signal decomposition: the wavelet representation. IEEE Trans Pattern Anal Mach Intell. 1989;11:674-93.
58. Arlot S, Celisse A. A survey of cross-validation procedures for model selection. Stat Surveys. 2010;4:40-79.
59. Richard R, Thomassin I, Chapellier M, Scemama A, de Cremoux P, Varna M, et al. Diffusion-weighted MRI in pretreatment prediction of response to neoadjuvant chemotherapy in patients with breast cancer. Eur Radiol. 2013;23:2420-31.
60. Juntu J, Sijbers J, Van Dyck D. Classification of soft tissue tumors in MRI images using kernel PCA and regularized least square classifier. In: Proceedings of the 4th conference IASTED international conference. Innsbruck: Signal Processing, Pattern Recognition, and Applications; 2007. ISBN 978-0-88986-646-1.
61. Cocquyt VF, Blondeel PN, Depypere HT, Praet MM, Schelfhout VR, Silva OE, et al. Different responses to preoperative chemotherapy for invasive lobular and invasive ductal breast carcinoma. Eur J Surg Oncol. 2003;29:361-7.
62. Tubiana-Hulin M, Stevens D, Lasry S, Guinebretière JM, Bouita L, Cohen-Solal C, et al. Response to neoadjuvant chemotherapy in lobular and ductal breast carcinomas: a retrospective study on 860 patients from one institution. Ann Oncol. 2006;17:1228-33.